Aurobindo Pharma, through its subsidiary Aurobindo Pharma USA Inc., has recently finalized an agreement to acquire Lannett Company LLC, a well-established US-based manufacturer known for producing high-quality complex generic pharmaceuticals. The acquisition, valued at ₹2185 crore (approximately $250 million), signifies Aurobindo’s strategic initiative to broaden its U.S. manufacturing capabilities and product portfolio. This move is aimed at enhancing Aurobindo’s presence in the competitive pharmaceutical market.
With its headquarters based in Trevose, PA, Lannett has a rich history dating back to 1942 and has earned a reputation for successfully launching generic liquid medications and treatments for Attention-Deficit/Hyperactivity Disorder (ADHD). The company operates a state-of-the-art cGMP manufacturing facility spanning 425,000 square feet in Seymour, Indiana, USA. This facility has the capacity to produce various dosage forms, including tablets, capsules, powders, and liquids, with an annual output of approximately 3.6 billion tablets.
One of the key strengths of Lannett lies in its expertise in manufacturing controlled substances (non-opioids, specifically focusing on ADHD treatments) and generic liquids. In 2024, the company reported revenues of $286 million (₹2499 crore), which increased to $306 million (₹2674 crore) in 2025. This acquisition provides Aurobindo with access to Lannett’s profitable product line, bolstering its Contract Development and Manufacturing Organization (CDMO) business and granting access to a well-established U.S.-based manufacturing facility with significant expansion potential.
Aurobindo’s acquisition of Lannett strategically complements its existing capabilities and offerings by strengthening its presence in the U.S. generics market, particularly in the non-opioid controlled substances segment, where Lannett has excelled. This move enables Aurobindo to further diversify its product portfolio and venture into specialized therapeutic categories, enhancing its competitiveness in the pharmaceutical sector.
In addition to the acquisition of Lannett, Aurobindo also finalized an agreement to transfer the shares of CuraTeQ Biologics s.r.o. held by Helix Healthcare B.V. to Curateq Biologics B.V. These transactions highlight Aurobindo’s commitment to expanding its subsidiary network and exploring new avenues for growth and innovation in the biopharmaceutical industry. By strategically acquiring key players in the market, Aurobindo is poised to strengthen its position as a global pharmaceutical leader.
Key Takeaways:
– Aurobindo Pharma’s acquisition of Lannett Company represents a strategic move to enhance its U.S. manufacturing footprint and product portfolio.
– Lannett’s expertise in controlled substances and generic liquids will provide Aurobindo with valuable assets to strengthen its presence in the pharmaceutical market.
– The acquisition enables Aurobindo to access profitable products, expand its CDMO business, and diversify into specialized therapeutic categories.
– Aurobindo’s strategic acquisitions, including Lannett and CuraTeQ Biologics, underscore its commitment to growth and innovation in the biopharmaceutical sector.
Read more on thehindubusinessline.com